在接受纳塔利祖马布治疗的患有儿科发病多发性硬化症患者中,高NEDA和无PIRA

Marco Puthenparampil1, Marta Gaggiola1, Marta Ponzano1

  • 1From the Department of Neurosciences (M. Puthenparampil, M.G., G.Z., A.M., P.G.), University of Padua; Multiple Sclerosis Centre (M. Puthenparampil, M.G., G.Z., P.P., F.R., P.G.), and Day Hospital and Centre for Advanced Neurological Therapies Unit, University Hospital of Padua; Department of Health Sciences (M. Ponzano, F.B.), Section of Biostatistics, University of Genova; Padua Neuroscience Centre (A.M.), University of Padua; Paediatric Neurology and Neurophysiology Unit (M.N., S.S.), Department of Women's and Children's Health, University Hospital of Padua; Neuroimmunology Group (M.N., S.S.), Paediatric Research Institute "Città della Speranza", Padua; and Neuroradiology Unit (A.D.P.), University Hospital of Padua, Italy.

概括

纳塔利祖马布 (NTZ) 在治疗儿科发病多发性硬化症 (POMS) 和成人发病多发性硬化症 (AOMS) 的疗效和安全性相似. 这项研究支持NTZ作为POMS的高效治疗方法,特别是在预防不依赖复发活动 (PIRA) 的进展方面.